Jardiance 10mg Tab

Manufacturer
Boehringer Ingelheim (Malaysia) Sdn. Bhd.

Registraction Number
MAL24026012ACSZ

 

Content

• Active Ingredient: Each tablet contains 10 mg of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults:
  • Monotherapy when metformin is inappropriate due to intolerance.
  • Add-on combination therapy with other glucose-lowering medicinal products.
• Cardiovascular Disease: To reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
• Heart Failure: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic chronic heart failure.
• Chronic Kidney Disease: To reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.

• Dosage: 10 mg once daily, taken in the morning, with or without food.
• Missed Dose: If a dose is missed, it should be taken as soon as the patient remembers; however, a double dose should not be taken on the same day.
• Renal Impairment: In patients with an eGFR <45 mL/min/1.73 m², the glucose-lowering efficacy is reduced, and in those with an eGFR <30 mL/min/1.73 m², efficacy is likely absent. Therefore, if eGFR falls below 45 mL/min/1.73 m², additional glucose-lowering treatment should be considered if needed.